74 Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, with an estimated 1.9 million new cases and more than 900,000 deaths in 2022, according to the World Health Organization. Scientists in China have uncovered a novel molecular mechanism that could improve the diagnosis and treatment of colorectal cancer. The research, published in the journal Genes & Diseases, focuses on a long non-coding RNA called AC004854.2 and its role in activating the cancer-promoting gene c-MYC. The study was conducted by a collaborative team primarily from the Hangzhou Institute of Medicine at the Chinese Academy of Sciences, Shanghai Jiao Tong University, and Fudan University, who investigated how AC004854.2 reshapes c-MYC transcription to fuel colorectal cancer malignancy. AC004854.2 is significantly upregulated in colorectal cancer tissues and is strongly associated with poor clinical outcomes. Elevated expression of the molecule correlates with increased tumour aggressiveness and reduced overall survival across independent patient cohorts, highlighting its potential value as both a prognostic biomarker and a therapeutic target. The canonical WNT/beta-catenin pathway is known to frequently drive the c-MYC proto-oncogene in colorectal cancer, but the precise promoter-proximal regulatory networks governing its expression have remained incompletely understood. Researchers found that AC004854.2 directly binds to the RNA-binding protein PUF60, competitively disrupting the inhibitory PUF60–FUBP1 complex that normally suppresses c-MYC transcription at the far-upstream element region of the c-MYC promoter. Disassembly of this repressor complex enhances c-MYC transcriptional activation, increasing the expression of downstream cell cycle regulators, including CCND2 and CDK4. Further investigation identified the transcription factor SOX4 as an upstream activator of AC004854.2, directly binding its promoter region and enhancing its transcription. This establishes a SOX4–AC004854.2–c-MYC signalling axis that drives colorectal cancer progression, integrating transcriptional regulation, RNA-mediated signalling, and oncogene activation into a single mechanistic framework. Functional experiments showed that AC004854.2 exerts broad pro-tumourigenic effects in colorectal cancer cells. Overexpression significantly enhanced cellular proliferation, migration, invasion, and cell cycle progression, while silencing the RNA suppressed malignant behaviour. In vivo studies confirmed that AC004854.2 promotes tumour growth and progression in animal models. Notably, the oncogenic effects were markedly reduced by treatment with IZCZ 3, a selective c-MYC inhibitor, demonstrating that the tumour-promoting activity of AC004854.2 depends heavily on c-MYC signalling and providing strong preclinical evidence for therapeutic targeting of this pathway. In the UK, bowel cancer accounts for around 48,000 new cases and 17,700 deaths annually, according to Cancer Research UK. Survival rates stand at approximately 54% for 10 years or more. Early detection through screening programmes has helped stabilise or reduce rates in high-income countries, yet the global burden continues to rise, particularly among younger adults in some populations, underscoring the need for new targeted approaches. Lead researchers, including Yanjie Chen, emphasise that the long non-coding RNA could serve as a new indicator for patient risk stratification and that strategies to inhibit AC004854.2 or its downstream effects on c-MYC may yield effective treatments for patients with advanced or hard-to-treat disease. Further studies will be needed to translate these findings into clinical tools, such as blood-based tests for AC004854.2 levels or drugs targeting the SOX4–AC004854.2–c-MYC axis. Experts not involved in the study have welcomed the findings, noting that colorectal cancer heterogeneity makes personalised medicine essential and that identifying specific molecular drivers, like this long non-coding RNA, could help tailor therapies more effectively and improve outcomes for thousands of patients each year.